HONG KONG – With a nod to proceed from the Korea Food and Drug Administration, Seoul-based Kainos Medicine Inc. is taking its Parkinson's disease candidate, KR-33493, into the clinic with the belief that it represents a fundamental improvement in the battle against the disease as the first to potentially alter Parkinson's rather than just addressing the symptoms.